Abstracts tagged "rheumatoid arthritis (RA) and vaccines"

Abstract Number: 1503 • 2016 ACR/ARHP Annual Meeting
Patterns and Factors Associated with Immunization Among Adult Patients with Rheumatic Diseases in the US
Huifeng Yun¹, Shuo Yang², Sofia Pedro³, Jeffrey Curtis⁴ and Kaleb Michaud⁵, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³National Data Bank for Rheumatic Diseases, Wichita, KS, ⁴Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rates of adult vaccination are low in patients with autoimmune disease despite broad recommendations for many years. In the U.S., pneumococcal vaccination is recommended…
Abstract Number: 1520 • 2015 ACR/ARHP Annual Meeting
Safety, Clinical and Immunologic Effectiveness of the Live Zoster Vaccine Administered to Patients Receiving Anti-TNF Biologics
Jeffrey R. Curtis^1,2, Anita Turner³, Corretta Thomas⁴, Stacey Cofield⁴, Randall Parks⁵, Jennifer H. Ku⁶, Ilhem Messaoudi- Powers⁷, Keith Wanzeck¹ and Kevin L. Winthrop⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama-Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴School of Public Health, University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Casey Eye Institute, Oregon Health & Science Univ, Portland, OR, ⁷Oregon Health and Sciences University, Portland, OR, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: The live herpes zoster vaccine (ZV) has been shown to be safe and effective in large randomized controlled trials of older adults. It is…
Abstract Number: 1554 • 2015 ACR/ARHP Annual Meeting
Severe Pneumonia after a 13-Prevalent Pneumonoccal Conjugate Vaccine (Prevena 13) Among Patients with Rheumatoid Arthritis
Sung Hae Chang¹ and Seong-Su Nah², ¹internal medicine, seoul national university, seoul, South Korea, ²Soonchunhyang clinical medical research center, Department of Soonchunhyang clinical medical research center, Choenan, South Korea
Background/Purpose: Disease modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) and biologics were ported to attenuate response to a previous 23-prevalent pneumococcal polysaccharide vaccine. Recently, a…
Abstract Number: 1576 • 2015 ACR/ARHP Annual Meeting
Effect of Conventional Synthetic and Biological Disease Modifying Anti-Rheumatic Drugs on the Immunogenicity of Hepatitis B Vaccine in Patients with Rheumatoid Arthritis
Samanan Intongkam¹, Rattapol Pakchotanon², Sumapa Chaiamnuay², Paijit Asavatanabodee² and Pongthorn Narongroeknawin², ¹Internal medicine, Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand, ²Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand
Background/Purpose: Immunogenicity of pneumococcal and influenza vaccine in patients with rheumatoid arthritis (RA) have been assessed in many studies. However, the humoral immune response of…
Abstract Number: 1585 • 2015 ACR/ARHP Annual Meeting
Vaccination Uptake in Patients with Rheumatoid Arthritis Treated with Disease-Modifying Anti-Rheumatic Drug Therapy: A Retrospective Cohort Study Using UK Primary Care Electronic Medical Records
Ruth Costello¹, Kevin L. Winthrop², Stephen R Pye¹ and William G Dixon³, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Oregon Health and Science University, Portland, OR, ³Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: The guidelines for the management of rheumatoid arthritis (RA) recommend an annual influenza vaccine and a pneumonia vaccination (EULAR, 2011), prior to starting disease-modifying…
Abstract Number: 2044 • 2014 ACR/ARHP Annual Meeting
Systematic Review of the Effect of Anti-Rheumatic Therapies upon Vaccine Immunogenicity
Megan Whittaker¹, James Galloway¹ and Sujith Subesinghe², ¹King's College London, London, United Kingdom, ²King's College Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose Patients with rheumatoid arthritis (RA) are at increased risk of infection compared to the general population. The increased risk is attributable to factors relating…
Abstract Number: 1348 • 2014 ACR/ARHP Annual Meeting
Improvement in Herpes Zoster Vaccination and Documentation for Rheumatoid Arthritis Patients Using Electronic Medical Record
Heena Sheth¹, Siamak Moghadam-Kia¹, Rayford June², Hilary J. Peterson¹, Davi Sa Leitao³, Larry W. Moreland⁴ and Rohit Aggarwal¹, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Despite increased risk of herpes zoster (HZ) in rheumatoid arthritis (RA) patients on immunosuppressive medication, American College of Rheumatology guidelines on HZ vaccination in…
Abstract Number: 1347 • 2014 ACR/ARHP Annual Meeting
Understanding Vaccination Rates Among Patients with Rheumatoid Arthritis
Diana S Sandler¹, Eric M. Ruderman², Tiffany Brown³, Ji Young Lee³, Amanda Ozanich³, David T Liss³ and David W Baker³, ¹Medicine/Rheumatology, Northwestern University, Chicago, IL, ²Div of Rheumatology, Northwestern University, Chicago, IL, ³Northwestern University, Chicago, IL
Background/Purpose: Vaccinations are important for patients with rheumatoid arthritis (RA) who may receive immunosuppressive therapies that increase their risk of infection. The Advisory Committee on…
Abstract Number: 1346 • 2014 ACR/ARHP Annual Meeting
Leveraging Electronic Health Records to Improve Vaccination Rates for Patients with Rheumatoid Arthritis
David W Baker¹, Tiffany Brown¹, Ji Young Lee¹, Diana S Sandler², David T Liss¹, Amanda Ozanich¹, Elizabeth Harsha Strong³, Alpa Patel¹ and Eric M. Ruderman⁴, ¹Northwestern University, Chicago, IL, ²Medicine/Rheumatology, Northwestern University, Chicago, IL, ³Rheumatology, Northwestern University, Chicago, IL, ⁴Div of Rheumatology, Northwestern University, Chicago, IL
Background/Purpose: Vaccination rates among patients with rheumatoid arthritis (RA) remain low. Improving these rates is important, as RA patients are inherently immunocompromised and frequently treated…
Abstract Number: 1344 • 2014 ACR/ARHP Annual Meeting
Electronic Medical Record-Based Best Practice Alert Used By Clinical Staff Improved Pneumococcal Vaccination and Documentation Among Immunosuppressed Rheumatoid Arthritis Patients
Heena Sheth¹, Larry W. Moreland², Hilary J. Peterson¹ and Rohit Aggarwal¹, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The Centers for Disease Control and American College of Rheumatology guidelines recommend pneumococcal vaccination for all immunosuppressed patients, specifically those taking disease modifying antirheumatic…
Abstract Number: 1920 • 2013 ACR/ARHP Annual Meeting
Determining The Vaccination Rates Of American College Of Rheumatology Recommended Vaccines Among Veterans With Rheumatoid Arthritis – A Quality Indicator
Puneet Bajaj¹, Melinda Collins² and Ranjan Roy¹, ¹Rheumatology, VA Medical Center, Northport, NY, ²Internal Medicine, VA Medical Center, Northport, NY
Background/Purpose: American College of Rheumatology (ACR) guidelines recommends the administration of killed vaccines [pneumococcal, influenza and hepatitis B (HepB)], recombinant human papillomavirus (HPV) vaccine and…
Abstract Number: 1046 • 2013 ACR/ARHP Annual Meeting
Comparison Of The Incidence Of Influenza Like Illness In Pregnant Women With Rheumatoid Arthritis and Women Without Rheumatoid Arthritis Who Receive An Influenza Vaccination
Yunjun Luo¹, Diana L. Johnson², Ronghui Xu³ and Christina D. Chambers¹, ¹Pediatrics, University of California, San Diego, La Jolla, CA, ²University of California San Diego Department of Pediatrics, La Jolla, CA, ³Family and Preventive Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: Influenza infection poses significant risk to pregnant women, therefore it is recommended that all pregnant women be vaccinated. However, it is unknown whether the…
Abstract Number: 2465 • 2012 ACR/ARHP Annual Meeting
Seroresponse Rates After Influenza Vaccination in Rheumatoid Arthritis Patients Treated with Biological Agents During the 2011–2012 Flu Season
Masatoshi Hayashi¹, Toshihisa Kojima², Naoki Ishiguro³, Tomonori Kobayakawa⁴ and Toshihisa Kanamono¹, ¹Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya Univeristy, School of Medicine, Nagoya, Japan, ³Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, ⁴Orthopedic Surgery, Nagoya university, Nagoya, Japan
Background/Purpose: At present, annual vaccination against influenza is recommended for rheumatoid arthritis (RA) patients. However, whether humoral responses to influenza vaccine are impaired in RA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].